Placebo for nirmatrelvir
Sponsors
Pfizer
Conditions
COVID-19Child, HospitalizedCoronavirus Disease 2019 (COVID-19)HospitalizationImmunocompromisedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Phase 2
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
CompletedNCT05438602
Start: 2022-08-03End: 2023-11-13Updated: 2024-09-23
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
WithdrawnNCT05545319
Start: 2022-12-13End: 2024-01-06Updated: 2023-03-01
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
CompletedNCT05567952
Start: 2022-10-19End: 2024-02-09Updated: 2024-10-08